Khawaja X, Evans N, Reilly Y, Ennis C, Minchin M C
Department of Molecular Pharmacology, Wyeth Research (U.K.), Maidenhead, Berkshire, England.
J Neurochem. 1995 Jun;64(6):2716-26. doi: 10.1046/j.1471-4159.1995.64062716.x.
The specific binding of [3H]WAY-100635 (N-[2-[4-(2-[O-methyl-3H]methoxyphenyl)-1-piperazinyl]ethyl]-N- 2-pyridinyl) cyclohexane carboxamide trihydrochloride) to rat hippocampal membrane preparations was time, temperature, and tissue concentration dependent. The rates of [3H]WAY-100635 association (k+1 = 0.069 +/- 0.015 nM-1 min-1) and dissociation (k-1 = 0.023 +/- 0.001 min-1) followed monoexponential kinetics. Saturation binding isotherms of [3H]WAY-100635 exhibited a single class of recognition site with an affinity of 0.37 +/- 0.051 nM and a maximal binding capacity (Bmax) of 312 +/- 12 fmol/mg of protein. The maximal number of binding sites labelled by [3H]WAY-100635 was approximately 36% higher compared with that of 8-hydroxy-2-(di-n-[3H]-propylamino) tetralin ([3H]8-OH-DPAT). The binding affinity of [3H]WAY-100635 was significantly lowered by the divalent cations CaCl2 (2.5-fold; p < 0.02) and MnCl2 (3.6-fold; p < 0.05), with no effect on Bmax. Guanyl nucleotides failed to influence the KD and Bmax parameters of [3H]WAY-100635 binding to 5-HT1A receptors. The pharmacological binding profile of [3H]WAY-100635 was closely correlated with that of [3H]8-OH-DPAT, which is consistent with the labelling of 5-hydroxytryptamine1A (5-HT1A) sites in rat hippocampus. [3H]WAY-100635 competition curves with 5-HT1A agonists and partial agonists were best resolved into high- and low-affinity binding components, whereas antagonists were best described by a one-site binding model. In the presence of 50 microM guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S), competition curves for the antagonists remained unaltered, whereas the agonist and partial agonist curves were shifted to the right, reflecting an influence of G protein coupling on agonist versus antagonist binding to the 5-HT1A receptor. However, a residual (16 +/- 2%) high-affinity agonist binding component was still apparent in the presence of GTP gamma S, indicating the existence of GTP-insensitive sites.
[3H]WAY-100635(N-[2-[4-(2-[O-甲基-3H]甲氧基苯基)-1-哌嗪基]乙基]-N-2-吡啶基)环己烷甲酰胺三盐酸盐)与大鼠海马膜制剂的特异性结合具有时间、温度和组织浓度依赖性。[3H]WAY-100635的结合速率(k+1 = 0.069 +/- 0.015 nM-1 min-1)和解离速率(k-1 = 0.023 +/- 0.001 min-1)遵循单指数动力学。[3H]WAY-100635的饱和结合等温线显示出一类识别位点,其亲和力为0.37 +/- 0.051 nM,最大结合容量(Bmax)为312 +/- 12 fmol/mg蛋白质。与8-羟基-2-(二-n-[3H]-丙基氨基)四氢萘([3H]8-OH-DPAT)相比,[3H]WAY-100635标记的结合位点最大数量高出约36%。二价阳离子CaCl2(2.5倍;p < 0.02)和MnCl2(3.6倍;p < 0.05)显著降低了[3H]WAY-100635的结合亲和力,对Bmax无影响。鸟苷酸未能影响[3H]WAY-100635与5-HT1A受体结合的KD和Bmax参数。[3H]WAY-100635的药理学结合图谱与[3H]8-OH-DPAT密切相关,这与大鼠海马中5-羟色胺1A(5-HT1A)位点的标记一致。[3H]WAY-100635与5-HT1A激动剂和部分激动剂的竞争曲线最好解析为高亲和力和低亲和力结合成分,而拮抗剂最好用单点结合模型描述。在50 microM鸟苷5'-O-(3-硫代三磷酸)(GTPγS)存在下,拮抗剂的竞争曲线保持不变,而激动剂和部分激动剂曲线向右移动,反映了G蛋白偶联对激动剂与拮抗剂结合到5-HT1A受体的影响。然而,在GTPγS存在下,仍有残余的(16 +/- 2%)高亲和力激动剂结合成分明显,表明存在对GTP不敏感的位点。